Tesamorelin

Overview

Tesamorelin is a synthetic, stabilized analogue of growth hormone-releasing hormone (GHRH). Rather than replacing growth hormone directly, it acts one step upstream: it prompts the pituitary gland to secrete the body's own growth hormone in a natural, pulsatile rhythm, which in turn raises IGF-1. Its best-documented effect is a reduction in visceral adipose tissue, the metabolically active fat packed around the abdominal organs.

Evidence Quality

Tesamorelin has an unusually strong evidence base for a peptide. It is FDA-approved, and that approval rests on two large multicenter, double-blind, placebo-controlled phase 3 randomized trials, later reinforced by independent randomized trials and meta-analysis. The evidence is strongest for its approved use, visceral fat in HIV-associated lipodystrophy, and considerably thinner for the general, non-HIV body-composition and anti-aging uses that circulate online.

What the Research Shows

In the pivotal trials, roughly 26 weeks of daily tesamorelin reduced visceral adipose tissue by about 15 to 18 percent versus placebo, alongside modest improvements in triglycerides and, in some studies, liver fat. A 2014 JAMA trial specifically confirmed reductions in both visceral and hepatic fat. The benefits are not permanent: when the drug is stopped, visceral fat tends to return, and the trials did not show meaningful loss of subcutaneous fat.

Dosage Notes

The standard clinical dose is 2 mg injected subcutaneously once daily, and the newer Egrifta SV formulation delivers 1.4 mg. It is a daily peptide. Unlike long-acting growth hormone secretagogues such as CJC-1295 with DAC, tesamorelin has a short half-life and must be dosed every day to sustain the growth hormone pulse. It is typically injected into the abdomen with rotating sites.

Who Should Be Cautious

Because tesamorelin stimulates the GH/IGF-1 axis, it is not appropriate for everyone. It is contraindicated in pregnancy and in people with active cancer, and it should be used cautiously by anyone with diabetes or impaired glucose tolerance because it can raise blood sugar and HbA1c. IGF-1 can rise above the normal range. It is explicitly not intended for general weight loss or cosmetic fat reduction.

Availability

As a medicine, tesamorelin is prescription-only and sold under the brand names Egrifta, Egrifta SV, and Egrifta WR for HIV-associated lipodystrophy. Separately, it is widely sold by peptide vendors as a lyophilized research powder, for example a 10 mg vial supplied in a 3 mL glass vial. These research-grade products are labeled not for human consumption and are not manufactured, tested, or approved to pharmaceutical standards.

Bottom Line

Tesamorelin is one of the better-validated peptides available: a genuinely FDA-approved GHRH analogue that reliably shrinks visceral fat in its studied population. Its trade-offs are real, including daily injections, rising glucose and IGF-1, and a rebound in fat once stopped, and its evidence outside HIV-associated lipodystrophy is limited. Anyone considering it should treat it as a real drug with real monitoring needs, not a casual supplement.